Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Change in Receivables (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Change in Receivables for 16 consecutive years, with $6.5 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 1566.71% to $6.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 million through Dec 2025, up 169.82% year-over-year, with the annual reading at $5.2 million for FY2025, 169.82% up from the prior year.
  • Change in Receivables hit $6.5 million in Q4 2025 for Cumberland Pharmaceuticals, up from $113691.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $7.8 million in Q1 2022 to a low of -$3.4 million in Q2 2021.
  • Historically, Change in Receivables has averaged $219846.4 across 5 years, with a median of -$58225.0 in 2023.
  • Biggest five-year swings in Change in Receivables: surged 4421.45% in 2022 and later crashed 666.56% in 2024.
  • Year by year, Change in Receivables stood at -$3.0 million in 2021, then skyrocketed by 30.41% to -$2.1 million in 2022, then fell by 21.54% to -$2.5 million in 2023, then surged by 115.54% to $390841.0 in 2024, then skyrocketed by 1566.71% to $6.5 million in 2025.
  • Business Quant data shows Change in Receivables for CPIX at $6.5 million in Q4 2025, $113691.0 in Q3 2025, and -$171014.0 in Q2 2025.